12:00 AM
 | 
Mar 30, 1998
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lamivudine 3TC: Phase III; awaiting marketing approval

BCHE reported data from trials comparing the combination of lamivudine with Intron A versus either alone. A total of 226 patients were randomized to received 100 mg lamivudine once daily for 52 weeks, 10 MU Intron A three times weekly for 16 weeks or lamivudine for 8 weeks followed by combination treatment for 16 weeks. Patients were followed to week 64.

The primary end point was seroconversion...

Read the full 334 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >